Bragar Eagel & Squire, P.C. Reminds Zoetis, Inc. Investors to Contact the Firm Before the July 27th Lead Plaintiff Deadline

Bragar Eagel & Squire, P.C. Reminds Zoetis, Inc. Investors to Contact the Firm Before the July 27th Lead Plaintiff Deadline Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Melissa Fortunato Encourage Investors Who Suffered Losses In Zoetis (ZTS) To Contact Them Directly To Discuss Their Options July 10, 2026 12:51 ET | Source: Bragar Eagel & Squire Bragar Eagel & Squire If you purchased or acquired Zoetis securities between January 14, 2025 and May 6, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648. Click here to participate in the action. NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- What’s Happening? Bragar Eagel & Squire, P.C ., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Zoetis, Inc. (“Zoetis” or the “Company”) (NYSE:ZTS) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Zoetis securities between January 14, 2025 and May 6, 2026, both dates inclusive (the “Class Period”). Investors have until July 27, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Allegation Details: The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) veterinarian prescription growth and adoption of Zoetis’ Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) ...